Ran Brosh earned his BSc from the Tel Aviv University and his MSc and PhD from the Weizmann Institute of Science (Rehovot, Israel). During this time his research focused on the molecular biology of the p53 tumor suppressor and its roles in cancer, development and somatic cell reprogramming. For his postdoctoral training, Ran joined the lab of Dr. Ihor R. Lemischka at the Black Family Stem Cell Institute in the Icahn School of Medicine at Mount Sinai (New York, USA). During his postdoctoral training Ran has gained expertise and knowledge in the fields of Stem Cells, Regeneration and Development and has developed a unique and novel molecular methodology to study protein function in mammalian stem cells.


Area of Interest

Embryonic Stem Cells
Cancer Stem Cells/Tumor Initiating Cells
Tumor Suppressors Methods

top publication

1. Brosh R, Hrynyk I, Shen J, Waghray A, Zheng N & Lemischka IR. A dual molecular analog tuner for dissecting protein function in mammalian stem cells. Nature Chemical Biology (Under Consideration). 2016.
2. Brosh R*, Assia‐Alroy Y*, Molchadsky A, Bornstein C, Dekel E, Madar S, Shetzer Y, Rivlin N, Goldfinger N, Sarig R & Rotter V. p53 counteracts reprogramming by inhibiting mesenchymal‐to‐epithelial transition. Cell Death and Differentiation. 2013.
3. Bornstein C*, Brosh R*, Molchadsky A, Madar S, Goldstein I, Goldfinger N, Sarig H & Rotter V. SPATA18, a spermatogenesisassociated gene, is a novel transcriptional target of p53 and p63. Molecular & Cellular Biology. 2011.
4. Brosh R, Sarig R, Bar Natan E, Molchadsky A, Madar S, Bornstein C, Buganim Y, Shapira T, Goldfinger N, Paus R & Rotter V. p53‐dependent transcriptional regulation of EDA2R & its involvement in chemotherapy‐induced hair loss. FEBS Letters. 2010.
5. Brosh R & Rotter V. Transcriptional control of the proliferation cluster by the tumor suppressor p53. Molecular BioSystems. 2010.
6. Brosh R & Rotter V. When mutants gain new powers: news from the mutant p53 field. Nature Reviews Cancer. 2009.
7. Brosh R*, Shalgi R*, Liran A, Landan G, Korotayev K, Nguyen G.N, Enerly E, Johnsen H, Buganim Y, Solomon H, Goldstein I,Madar S, Goldfinger N, Børresen‐Dale A‐L, Ginsberg D, Harris C.C, Pilpel Y, Oren M & Rotter V. p53‐repressed miRNAs are involved with E2F in a feed forward loop promoting proliferation. Molecular Systems Biology. 2008. Featured in: Blattner C. \'Junk\' DNA meets the p53 network. Molecular Systems Biology. 2008.
8. Madar S*, Brosh R*, Buganim Y, Ezra O, Goldstein I, Solomon H, Kogan I, Goldfinger N, Klocker H & Rotter V. Modulated expression of WFDC1 during carcinogenesis & cellular senescence. Carcinogenesis. 2008.
9. Suad O*, Rozenberg H*, Brosh R*, Diskin‐Posner Y, Kessler N, Shimon LJW, Frolow F, Liran A, Rotter V & Shakked Z. Structural basis of restoring sequence‐specific DNA binding & transactivation to mutant p53 by suppressor mutations.Journal of Molecular Biology. 2008.
10. Tabach Y*, Milyavsky M*, Shats I*, Brosh R*, Zuk O, Yitzhaky A, Mantovani R, Domany E, Rotter V & Pilpel Y. The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Molecular Systems Biology. 2005.
Additional Publications:
11. Waghray A, Saiz N, Jayaprakash AD, Freire AG, Papatsenko D, Pereira C‐P, Lee D‐F, Brosh R, Chang B, Darr H, Gingold J, Kelley K, Schaniel C, Hadjantonakis A‐K, Lemischka IR. Tbx3 controls Dppa3 levels and exit from pluripotency toward mesoderm. Stem Cell Reports. 2015.
12. Landan G, Mendelson Cohen N, Mukamel Z, Bar A, Molchadsky A, Brosh R, Horn‐Saban S, Amann Zalcenstein D, Goldfinger N, Zundelevich A, Gal‐Yam EN, Rotter V & Tanay A. Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nature Genetics. 2012.
Featured in: Krebs AR & Schübeler D. Tracking the evolution of cancer methylomes. Nature Genetics. 2012.
v 13. Solomon H*, Buganim Y*, Kogan‐Sakin I, Pomeraniec L, Assia Y, Madar S, Goldstein I, Brosh R, Kalo E, Beatus T, Goldfinger N & Rotter V. Various p53 mutant types differently regulate the Ras circuit to induce a cancer‐related gene signature. Journal of Cell Science. 2012.
14. Buganim Y*, Madar S*, Rais Y, Pomeraniec L, Harel E, Haimov O, Avivi C, Polak‐Charcon S, Brait M, Solomon H, Goldstein I,Brosh R, Kalo E, Goldfinger N, Sidransky D, Barshack I, & Rotter V. The diverse functions of ATF3 in tumors & their microenvironment & its interaction with p53. Carcinogenesis. 2011.
15. Leshem O*, Madar S*, Kogan‐Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob‐Hirsch J, Ehrlich M, Ben‐Sasson S, Goldfinger N, Rotter V & Berger R. TMPRSS2:ERG promotes epithelial to mesenchymal transition through the Zeb1/2 Axis in a prostate cancer model. PLoS One. 2011.
16. Rivlin N, Brosh R, Kogan‐Sakin I & Rotter V. Mutations in the p53 tumor suppressor gene, important milestones in tumorigenesis. Genes & Cancer. 2011.
17. Sarig R*, Rivlin N*, Brosh R, Bornstein C, Kamer I, Ezra O, Molchadsky A, Goldfinger N, Brenner O & Rotter V. Mutant p53 displays a novel gain of function in the process of somatic cell reprogramming. The Journal of Experimental Medicine. 2010.
18. Buganim Y*, Goldstein I*, Lipson D, Milyavsky M, Polak‐Charcon S, Mardoukh C, Solomon H, Kalo E, Madar S, Brosh R, Perelman M, Navon R, Goldfinger N, Barshack I, Yakhini Z & Rotter V. a novel translocation breakpoint within the BPTF gene is associated with a pre‐malignant phenotype. PLoS One. 2010.
19. Solomon H, Brosh R, Buganim Y & Rotter V. Inactivation of the p53 tumor suppressor gene & activation of the Ras oncogene:cooperative events in tumorigenesis. Discovery Medicine. 2010.
20. Molchadsky M, Rivlin R, Brosh R, Rotter V & Sarig R. p53 is balancing development, differentiation and de‐differentiation to prevent tumorigenesis. Carcinogenesis. 2010.
21. Buganim Y*, Solomon H*, Rais Y, Kistner D, Ido N, Beatus T, Madar S, Goldstein I, kalo E, Adam N, Yaskavich M, Rivlin N, Kogan I, Brosh R, Sefadia‐Elad G, Goldfinger N, Kloog Y & Rotter V. p53 regulates the Ras circuit to inhibit the expression of a cancerrelated gene signature by various molecular pathways. Cancer Research. 2010.
22. Shalgi R, Brosh R, Oren M, Pilpel Y & Rotter V. Coupling transcriptional and post‐transcriptional miRNA regulation in the control of cell fate. Aging. 2009.
23. Kogan‐Sakin I*, Cohen M*, Paland N, Madar S, Solomon H, Molchadsky A, Brosh R, Buganim Y, Goldfinger N, Klocker H, Schalken JA & Rotter V. Prostate stromal cells produce CXCL‐1, CXCL‐2, CXCL‐3 and IL‐8 in response to epithelia‐secreted IL‐1. Carcinogenesis. 2009.
24. Tabach Y, Brosh R, Buganim Y, Reiner A, Zuk O, Yitzhaky A, Koudritsky M, Rotter V & Domany E. Wide‐scale analysis of human functional transcription factor binding reveals a strong bias towards the transcription start site. PLoS One. 2007.
25. Shats I, Milyavsky M, Cholostoy A, Brosh R & Rotter V. Myocardin in tumor suppression and myofibroblast differentiation.Cell Cycle. 2007.
26. Milyavsky M*, Shats I*, Cholostoy A, Brosh R, Buganim Y, Weisz L, Kogan I, Cohen M, Shatz M, Madar S, Kalo E, Goldfinger N, Yuan J, Ron S, MacKenzie K, Eden A & Rotter V. Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect. Cancer Cell. 2007.
27. Buganim Y, Kalo E, Brosh R, Besserglick H, Nachmany I, Rais Y, Stambolsky P, Tang X, Milyavsky M, Shats I, Kalis M, Goldfinger N & Rotter V. Mutant p53 protects cells from 12‐O‐tetradecanoylphorbol‐13‐acetate‐induced death by attenuating activating transcription factor 3 induction. Cancer Research. 2006.
28. Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R, Kogan I, Braunstein I, Tzukerman M, Ginsberg D & Rotter V. p53‐dependent down‐regulation of telomerase is mediated by p21waf1. The Journal of Biological Chemistry. 2004.